Why Preimplantation Genetic Testing has been a bustPosted by Mrudula Anil Karmarkar on June 4th, 2021 The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth. High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology. A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market. Rising incidence single gene,mitochondrial, and other gene-related disorders, are attributed to increasing demand for preimplantation diagnosis and screening processes. As per the estimates made by the Florida Department of Health, about one in every 28 babies is diagnosed with a birth defect in Florida each year. Preimplantation Genetic Diagnosis (PGD) is implemented prior to IVF workflow for successful pregnancy. PGD is applicable in IVF cycles of women who faced several miscarriages or had last pregnancy with a chromosome abnormality. PGD can benefit the couples who are at risk of hereditary disorders, positively influencing the market. The concept of aneuploidy screening during PGD has enhanced the IVF procedures. The introduction of aneuploidy testing in IVF centers identifies abnormal embryos; resulting in successful pregnancy rates. In August 2018, a study of Fertility and Sterility analyzed the successful IVF pregnancy outcomes by using Natera’s Spectrum PGT for aneuploidy (PGT-A). Further key findings from the report suggest:
Moreover, subsequent innovations in genetic diagnosis such as an introducing PGT monogenic disease diagnosis (PGT-M), stimulates the industrial growth. PGT-M focus on identification of Mendelian genetic disorder in embryo for addressing challenges of prenatal diagnosis as it precludes the chances of elective termination of pregnancy. Number of supportive initiatives adopted by the government authorities to promote reproductive health, also drive the market. For instance, in June 2017, Switzerland government approved the pre-implantation genetic diagnosis of an in-vitro embryo. Such initiatives focus on detecting and minimizing genetic anomalies affecting embryos before implantation. Ethical acceptability and legal regulations by public entities impede the adoption rate of PGT services thereby hampering the growth. However, awareness regarding health of fetus among couples and expanding applications of PGD and Preimplantation Genetic Screening (PGS) collectively create opportunities for market progression. Have a Query? Ask Our Expert: https://www.grandviewresearch.com/inquiry/3258/ibb Some of the key players are Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatrix. Continuous developments incorporated by key participants in genetic diagnosis for successful implementation of PGT as well as screening, expands their market share significantly. Key players adopt several strategic initiatives such as geographical expansions, collaborative developments, and new product developments. Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application: Preimplantation Genetic Testing (PGT) PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)
Preimplantation Genetic Testing (PGT) (PGS/PGD) Type Outlook (Revenue, USD Million, 2014 - 2024)
Preimplantation Genetic Testing (PGT) (PGS/PGD) Application Outlook (Revenue, USD Million, 2014 - 2024)
About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. For More Information:www.grandviewresearch.com
Like it? Share it!More by this author |